Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.36)
# 312
Out of 4,784 analysts
124
Total ratings
40%
Success rate
32.97%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.42 | +374.83% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $6.50 | +207.69% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $0.49 | +512.24% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $14.78 | +136.81% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $13.82 | +174.96% | 7 | Feb 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $109 → $96 | $25.65 | +274.27% | 2 | Feb 7, 2025 | |
| NKTR Nektar Therapeutics | Initiates: Buy | $4 | $0.74 | +441.79% | 1 | Jan 8, 2025 | |
| CGTX Cognition Therapeutics | Upgrades: Buy | $1 → $1.5 | $0.42 | +260.84% | 3 | Dec 19, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $194 → $236 | $327.87 | -28.02% | 11 | Nov 5, 2024 | |
| NVAX Novavax | Reiterates: Buy | $23 → $26 | $7.00 | +271.43% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $14.59 | +126.18% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $26.21 | +90.77% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.32 | +275.94% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $39.86 | -14.70% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $5 | $1.26 | +296.83% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $43.19 | +113.01% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $4.04 | -0.99% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.24 | +1,544.06% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $3 | $0.25 | +1,100.00% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $1.60 | +9,900.00% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.89 | +164.55% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $1.65 | +2,566.67% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.61 | +5,490.06% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $7.52 | -6.91% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.33 | +338,245.86% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $1.01 | +26,632.67% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $11.58 | +564.94% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.59 | +90,466.04% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.52 | +163.16% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $88.93 | -56.15% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $11 | $1.45 | +658.62% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.67 | +826.43% | 1 | Mar 13, 2020 |
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.42
Upside: +374.83%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $6.50
Upside: +207.69%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.49
Upside: +512.24%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $14.78
Upside: +136.81%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $13.82
Upside: +174.96%
Viking Therapeutics
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $25.65
Upside: +274.27%
Nektar Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $4
Current: $0.74
Upside: +441.79%
Cognition Therapeutics
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.42
Upside: +260.84%
Madrigal Pharmaceuticals
Nov 5, 2024
Maintains: Neutral
Price Target: $194 → $236
Current: $327.87
Upside: -28.02%
Novavax
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $7.00
Upside: +271.43%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $14.59
Upside: +126.18%
Aug 29, 2024
Reiterates: Buy
Price Target: $50
Current: $26.21
Upside: +90.77%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $5.32
Upside: +275.94%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $39.86
Upside: -14.70%
Jul 31, 2024
Downgrades: Neutral
Price Target: $18 → $5
Current: $1.26
Upside: +296.83%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $43.19
Upside: +113.01%
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $4.04
Upside: -0.99%
Oct 13, 2023
Initiates: Buy
Price Target: $4
Current: $0.24
Upside: +1,544.06%
Apr 10, 2023
Maintains: Buy
Price Target: $7 → $3
Current: $0.25
Upside: +1,100.00%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $1.60
Upside: +9,900.00%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.89
Upside: +164.55%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $1.65
Upside: +2,566.67%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.61
Upside: +5,490.06%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $7.52
Upside: -6.91%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.33
Upside: +338,245.86%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $1.01
Upside: +26,632.67%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $11.58
Upside: +564.94%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.59
Upside: +90,466.04%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $1.52
Upside: +163.16%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $88.93
Upside: -56.15%
Mar 13, 2020
Maintains: Buy
Price Target: $22 → $11
Current: $1.45
Upside: +658.62%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.67
Upside: +826.43%